UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Diffuse Midline Glioma
Glioma
Brainstem Glioma
This phase 1/2 trial is evaluating the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy to treat children and young adults with newly diagnosed high-grade gliomas (HGGs) that have alterations in the gene that encodes histone 3 (H3 K27-altered).
Conditions
Diffuse Midline Glioma
This study will enroll children and young adults (between the ages of 3 to 21 years old) with newly diagnosed Diffuse Midline Gliomas (DMGs, HLA-A*0201 positive and H3.3K27M positive).
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Medulloblastoma
Choroid Plexus Tumors
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
The purpose is to evaluate cognitive, social, emotional, and behavioral functioning over time in patients already enrolled in a Children’s Oncology Group Phase III clinical trial.
Conditions
Diffuse Midline Glioma
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Glioblastoma
Brainstem Glioma
Ependymoma
This phase I clinical trial will evaluate ONC206 alone or in combination with radiation therapy in treating pediatric patients with newly diagnosed or recurrent DMGs, or other recurrent primary malignant brain tumors.
Conditions
Diffuse Midline Glioma